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Abstract Sphingosylphosphorylcholine (SPC) increased intra-
cellular Ca2+ concentration ([Ca2+]i) and nitric oxide (NO)
production in endothelial cells in situ on bovine aortic valves, and
induced endothelium-dependent relaxation of bovine coronary
arteries precontracted with U-46619. The SPC-induced vaso-
relaxation was inhibited by Ng-monomethyl-L-arginine, an
inhibitor of both constitutive and inducible NO synthase
(NOS), but not by 1-(2-trifluoromethylphenyl) imidazole, an
inhibitor of inducible NOS (iNOS). Immunoblotting revealed
that endothelial constitutive NOS, but not iNOS, was present in
endothelial cells in situ on the bovine aortic valves. We propose
that SPC activates [Ca2+]i levels and NO production of
endothelial cells in situ, thereby causing an endothelium-
dependent vasorelaxation.
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1. Introduction
Sphingolipids are novel second messengers mediating a va-
riety of cellular responses, including cell proliferation and
apoptosis. One of the sphingolipids, sphingosylphosphoryl-
choline (SPC), which is generated by sphingomyelin N-deacyl-
ation, induces elevation of intracellular Ca2 concentration
([Ca2]i) in various types of cultured cells [1^3]. However,
characterization of [Ca2]i elevation as induced by SPC has
remained to be elucidated.
In endothelial cells, elevation of [Ca2]i is a prerequisite for
cellular responses via production of nitric oxide (NO) and
prostacyclin, and the activation of other Ca2-dependent en-
zymes. A di¡usible gas, NO plays a most important role
through the activation of guanylyl cyclase in the endo-
thelium-dependent vasorelaxation. The formation of NO is
induced by nitric oxide synthase (NOS), which is classi¢ed
into constitutive NOSs (endothelial NOS and neural NOS)
and inducible NOS (iNOS) [4,5]. The constitutive NOSs, but
not iNOS, are activated by the elevation of [Ca2]i. In partic-
ular, the elevation of [Ca2]i caused by the in£ux of extra-
cellular Ca2, but not the release of intracellular Ca2, plays
an important role in the activation of endothelial NOS
(eNOS) [6]. However, it has not been clari¢ed whether or
not SPC can stimulate the in£ux of extracellular Ca2 in
endothelial cells. In addition, the physiological e¡ects of
sphingolipids on endothelial cells are not well understood.
We now provide the ¢rst evidence that SPC regulates vas-
cular tone by activating endothelial NO production, as evi-
denced by the following: (1) SPC induced a [Ca2]i increase,
as mediated by both the release of intracellular Ca2 and the
in£ux of extracellular Ca2 in endothelial cells in situ, (2) SPC
increased NO production in endothelial cells in situ, and (3)
SPC induced an endothelium-dependent vasorelaxation,
which was blocked by a NOS inhibitor.
2. Materials and methods
2.1. Materials
SPC was purchased from Sigma (St. Louis, MO, USA) or Biomol
(Plymouth Meeting, PA, USA). Adenosine 5P-triphosphate (ATP), U-
46619, and fatty acid-free bovine serum albumin were from Sigma.
Fura-2/AM and 2,3-diaminonaphthalene (DAN) were from Dojindo
(Kumamoto, Japan). Acetylated low-density lipoprotein labeled with
1,1P-dioctadecyl-3,3,3P,3P-tetramethyl-indo-carbocyanine perchlorate
(DiI-Ac-LDL) was from Biomedical Technologies Inc. (Massachu-
setts, USA). Ng-Monomethyl-L-arginine (L-NMMA) was from
Wako Pure Chemical (Osaka, Japan), and 1-(2-tri£uoromethylphenyl)
imidazole (TRIM) was from Calbiochem (San Diego, CA, USA).
Bradykinin (BK) was from Peptide Institute (Osaka, Japan). All other
chemicals were purchased from Katayama Chemical (Osaka, Japan).
Positive controls for the immunoblotting of eNOS (human endothelial
lysate) and iNOS (mouse macrophage lysate) were from Transduction
Laboratories Inc. (Lexington, KY, USA).
2.2. Preparations
Bovine aortic valves and coronary arteries were obtained from a
local abattoir immediately after the animals were killed. The tissue
specimens were placed in ice-cold physiological salt solution (PSS
(mM); 123 NaCl, 4.7 KCl, 15.5 NaHCO3, 1.2 KH2PO4, 1.2 MgCl2,
1.25 CaCl2, and 11.5 D-glucose) and transported to our laboratory.
All solutions were gassed with a mixture of 5% CO2 and 95% O2 (pH
adjusted to 7.4 at 37‡C). Endothelial cells in situ of aortic valves were
identi¢ed by their speci¢c uptake of DiI-Ac-LDL [7,8].
To analyze the expression of NOS, homogenates of endothelial cells
on bovine aortic valves were subjected to 7.5% SDS-polyacrylamide
gel electrophoresis. After blocking, the blots were incubated with anti-
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eNOS or anti-iNOS antibody (Transduction Laboratories Inc.) and
the antigens were visualized, as described [9].
2.3. Measurement of [Ca2+]i of the endothelial cells in situ
The endothelial cells in situ of bovine aortic valves were loaded with
10 WM fura-2/AM (the acetoxymethyl ester form of fura-2), as de-
scribed [7,8,10]. Using double staining with DiI-Ac-LDL and fura-2,
we con¢rmed that fura-2 £uorescence was exclusively emitted from
the endothelial cells on the surface of the aortic valves, as described
[7,8]. Changes in [Ca2]i were continuously monitored with £uores-
cence intensities (510 nm) at alternating 340 nm (F340) and 380 nm
(F380) excitation and their ratio (R = F340/F380) in a spectro£uorometer
(Hitachi F2000), all operated using our own program. Before the start
of the experimental protocol, strips of aortic valves were stimulated
with 10 WM ATP for 1 min to con¢rm a reference response. The
£uorescence ratio values were normalized by assigning the values in
normal PSS and at the peak response to 10 WM ATP to be 0% and
100%, respectively.
2.4. Measurements of NO production of the endothelial cells in situ
To assess NO production in endothelial cells in situ, we measured
the concentration of nitrite in PSS using a £uorometry of DAN ac-
cording to the method of Misko et al. [11], except that 5 mM EDTA
was ¢rst added to sample solutions to avoid the possible interference
with a £uorescence measurement of DAN by divalent cations [12].
Before application of 20 WM SPC, strips of aortic valves were stimu-
lated for 3 min by a well-known activator of eNOS, 10 WM ATP [13],
as a reference response. ATP, SPC or vehicle was applied to the aortic
valve (5U8 mm) pinned in the Sylgard chamber by exchanging the
solutions (600 Wl). At the end of the treatment (3 min), the solution
was aspirated from the chamber and used for nitrite measurements.
To determine the basal NO production in endothelial cells in situ at
rest, fresh PSS (600 Wl) was applied to the aortic valve for 3 min and
was collected before each experiment.
The intensity of the £uorescent signal generated by 1-(H)-naphtho-
triazole, the product of the reaction between nitrite and DAN, was
measured with excitation at 365 nm and emission at 405 nm, using a
spectro£uorometer (Hitachi F2000). The limit of detection of nitrite
concentration in PSS was 10 nM. Standard sodium nitrite solutions
(10 nM^1 WM) were freshly prepared to obtain a standard curve
regarding the relationship between £uorescence intensity and nitrite
concentration in PSS, for each measurement. The level of NO pro-
duction was expressed as a percentage, assigning value at the ‘zero’
level ( = background £uorescence of solution only, without the aortic
valves) and the value obtained from the aortic valves at rest (treated
with fresh PSS for 3 min) to be 0% and 100%, respectively.
We also used a three-electrode potentiostatic EMS-100 system
(BIO-LOGIC, France) to measure NO production directly [14]. In
each experiment NO biosensor calibration was performed by cumu-
lative applications of various concentrations of NO standard solu-
tions. The NO stock solution (1.4 mM) was made by saturating dis-
tilled water with NO gas for 30 min after substitution of all the
dissolved gases with Ar gas, as described [15]. The NO biosensor is
speci¢c for NO and did not respond to nitrite (up to 10 WM). The NO
biosensor was positioned about 10 Wm above the aortic valve (5U8
mm), which was pinned in the chamber ¢lled with 600 Wl PSS. Six Wl
of 2 mM SPC (¢nal concentration 20 WM) was added to the chamber
by pipetting.
2.5. Force recording of arterial rings with or without endothelium
The bovine coronary arterial rings were mounted vertically at the
organ bath ¢lled with PSS, gassed with 5% CO2 and 95% O2, and
maintained at 37‡C. A force transducer (TB-611T, Nihon Koden,
Japan) was used to measure the isometric force [8]. In an equilibration
period of 1 h, a passive force of about 2 g was applied to the rings,
and high-K PSS (118 mM K) was applied repeatedly to reach a
steady amplitude. After recording a reference response to 118 mM K
depolarization, the e¡ects of 20 WM SPC on the force were examined
at the plateau phase of the precontraction induced by 100 nM U-
46619 (9,11-dideoxy-9K,11K-epoxymethanoprostaglandin F2K), and
thereafter NOS inhibitors (100 WM TRIM and 3 mM L-NMMA)
were added. The remaining endothelium was examined by application
of 1 WM BK. In some strips, the endothelium was removed by rubbing
with a cotton web.
3. Results and discussion
3.1. SPC-induced changes in [Ca2+]i in endothelial cells in situ
SPC dose-dependently (1^30 WM) induced [Ca2]i elevation,
which consisted of an initial transient and a subsequently
sustained plateau phase (Figs. 1A and 2). The observed
SPC-induced increase in [Ca2]i is not simply due to a non-
speci¢c, lipid-induced hyperpermeabilization of the cell
membrane, since after washing SPC, the [Ca2]i reverted to
the prestimulation level and the [Ca2]i elevation induced by
Fig. 1. Representative recordings showing changes in [Ca2]i induced by 20 WM SPC, under various conditions. SPC (20 WM) was applied 15
min after the stimulation with 10 WM ATP in PSS (1.25 mM Ca2 ; A), under blockade of Ca2 in£ux with Ni2 (B), and in the absence of ex-
tracellular Ca2 (C). Extracellular Ca2 was restored in the absence (D) and presence (C) of SPC.
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10 WM ATP was reproduced. In addition, neither sphingosine
nor phosphorylcholine (up to 30 WM) induced [Ca2]i eleva-
tion (data not shown), thus supporting the notion of a speci¢c
e¡ect of SPC on the [Ca2]i in the endothelial cells in situ. To
estimate the relative contribution of extracellular Ca2 to the
SPC-induced [Ca2]i changes, SPC was applied either in the
presence of 1 mM Ni2 or in the absence of extracellular Ca2
(bu¡ered with 2 mM EGTA). Blockade of the Ca2 in£ux
with Ni2 abolished the sustained elevation of [Ca2]i induced
by SPC, whereas the initial transient elevation of [Ca2]i re-
mained (Fig. 1B). An identical result was obtained when SPC
was applied in the absence of extracellular Ca2 (Fig. 1C). Re-
application of Ca2 restored the sustained elevation of [Ca2]i
induced by SPC (Fig. 1C), whereas this procedure in the ab-
sence of SPC did not generate a [Ca2]i elevation above the
resting level (Fig. 1D). These ¢ndings suggest that the [Ca2]i
elevation induced by SPC may be mediated by both the in£ux
of extracellular Ca2 and the release of intracellular Ca2 in
endothelial cells in situ.
We found that the SPC-induced transient elevation of
[Ca2]i is mediated by the release of intracellular Ca2 (Fig.
1), which may involve activation of the recently reported nov-
el Ca2 channels at store sites [16]. In the present study, we
demonstrated for the ¢rst time that SPC stimulates the in£ux
of extracellular Ca2, thereby inducing the sustained elevation
of [Ca2]i in endothelial cells in situ (Fig. 1). Cellular mech-
anisms of the SPC-induced in£ux of extracellular Ca2 are
unknown. SPC is reported to activate the K channels, there-
by inducing hyperpolarization in guinea pig atrial myocytes
[17]. Therefore, SPC may increase Ca2 in£ux by activating
K channels in the endothelial cells, since Ca2 in£ux in en-
dothelial cells is enhanced by the hyperpolarization of mem-
brane potential [18]. Recently it was reported that sphingosine
1-phosphate (SPP), one of the sphingolipids, is a ligand for
the G protein-coupled receptor EDG1 [19] and activates phos-
pholipase C, which in turn produces inositol 1,4,5-trisphos-
phate (IP3), a trigger of Ca2 release [20]. SPC and SPP in-
creased the [Ca2]i in endothelial cells in situ, with a similar
potency (EC50 = 5 WM for SPC and 1 WM for SPP) in the
present study (unpublished data). In contrast, SPC is much
less potent than SPP for activating the reported sphingolipid
receptors (EDG1, EDG3, and H218): the EC50 values of SPC
and SPP are 100 nM and 1 nM (for EDG1), 100 nM and 10
nM (for EDG3), and 50 nM and 5 nM (for H218), respec-
tively [20,21]. Therefore, it is unlikely that the sphingolipid
receptors have an important role in the SPC-induced [Ca2]i
elevations, at least in endothelial cells in situ.
3.2. SPC-induced NO production
It has been reported that in£ux of extracellular Ca2 is
essential for the activation of eNOS and the resultant stimu-
Fig. 2. Concentration-response curves for the SPC-induced [Ca2]i
elevations. Abscissa, concentration of SPC; ordinate, the levels of
the [Ca2]i elevations (% of the 10 WM ATP-induced response).
Open and closed symbols indicate the levels of an initial transient
and a subsequently sustained elevation of [Ca2]i, respectively. The
data were obtained from ¢ve separate experiments (as carried out
according to the protocol shown in Fig. 1A) for each dose and are
expressed as mean þ S.E.M.
Fig. 3. A: E¡ects of 10 WM ATP and 20 WM SPC on NO produc-
tion in endothelial cells in situ. NO production (3 min) was ex-
pressed as a percentage, assigning the value obtained at rest
( = basal NO production by endothelial cells in situ) to be 100%. Ve-
hicle was that of 20 WM SPC and consisted of 0.2% ethanol, 0.02
mg/ml bovine serum albumin, and 1% PBS. The data were obtained
from four separate experiments and are expressed as means þ S.E.M.
*P6 0.05 by Student’s t-test was considered to be signi¢cant. B: A
representative di¡erential pulse amperogram obtained with NO bio-
sensor after application of 20 WM SPC.
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lation of NO production in endothelial cells [6]. Therefore, in
order to investigate the functional role of the SPC-induced
[Ca2]i elevation, NO production in endothelial cells in situ
was assessed not only by a £uorometric measurement of the
production of nitrite using DAN but also by a direct measure-
ment of NO using a NO electrode.
Fluorometry of DAN revealed that SPC (20 WM) and ATP
(10 WM) signi¢cantly increased NO production at 3 min
(P6 0.05), although a vehicle for SPC had no stimulatory
e¡ect on NO production (Fig. 3A).
The di¡erential pulse amperogram obtained with the NO
biosensor is shown in Fig. 3B. SPC (20 WM) induced a rapid
elevation of NO concentration, with a maximum elevation of
186 nM, whereas no change was induced by a simple addition
of PSS. SPC (up to 20 WM) solution itself, without aortic
valves, had no e¡ect on the amperogram of the NO biosensor
(data not shown). Using these two di¡erent (biochemical and
electrophysiological) techniques for the NO measurements, we
obtained evidence that SPC stimulates NO production in en-
dothelial cells in situ.
eNOS is constitutively expressed in endothelial cells, where-
as iNOS is induced by various stimuli, such as interferon,
lipopolysaccharide, and trauma [4]. We examined the expres-
sion of the NOS isoforms in endothelial cells in situ on bovine
aortic valves, using immunoblotting with antibodies against
eNOS and iNOS. Anti-eNOS antibody recognized a protein
with an approximate molecular mass of 140 kDa both in
homogenates of endothelial cells in situ on bovine aortic
valves and in human endothelial lysate used as positive con-
trol for eNOS (Fig. 4A). The band at 140 kDa was undetect-
able in mouse macrophage lysate used as positive control for
iNOS (Fig. 4A). The band at 140 kDa was prevented by
preadsorption of anti-eNOS antibody with puri¢ed bovine
eNOS protein, and the staining was not observed without
Fig. 4. Western blot analysis of endothelial cells (10 Wg of protein) of bovine aortic valve. Lanes a and b are positive controls for iNOS (mouse
macrophage lysate) and for eNOS (human endothelial lysate), respectively. Lane c is homogenates of endothelial cells in situ of bovine aortic
valve.
Fig. 5. Representative recordings showing the e¡ects of 20 WM SPC on the contraction of the bovine coronary arteries, with (A) and without
(B) endothelium, precontracted by 100 nM U-46619. The e¡ects of the selective inhibitor for iNOS (100 WM TRIM) and of non-selective NOS
inhibitor (3 mM L-NMMA) on the SPC-induced vasorelaxation were also observed. The presence (A) and absence (B) of endothelium was as-
sessed by the presence and absence of the relaxing response to 1 WM BK, respectively.
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treatment of anti-eNOS antibody (data not shown). On the
other hand, anti-iNOS antibody recognized a protein with an
approximate molecular mass of 130 kDa in mouse macro-
phage lysate, but not in homogenate of endothelial cells and
human endothelial lysate (n = 10) (Fig. 4B). These observa-
tions indicate that eNOS, but not iNOS, is mainly expressed
in the endothelial cells in situ on the bovine aortic valves used
in the present study. Taken together, the ¢ndings of the
present study suggest that SPC activates eNOS through
[Ca2]i elevation and thereby stimulates NO production in
endothelial cells in situ.
SPC stimulated the NO production more strongly than
ATP did, while the SPC-induced [Ca2]i elevation was smaller
than that induced by ATP. These results are compatible with
the idea that SPC potentiates the Ca2 sensitivity of NO pro-
duction, supporting its regulatory role for the activation of
eNOS. Direct interaction of eNOS with caveolin, a sca¡olding
protein in caveolae, inhibits the eNOS activity and promotes
sequestration of inactive eNOS within caveolar microdo-
mains, by acylation in the N-terminal region of eNOS [22^
25]. Ca2-calmodulin promotes the dissociation of caveolin
from eNOS and therefore activates eNOS [26]. Since SPC
has an alkyl chain with a hydroxy moiety as well as an acyl
chain in the molecular structure, SPC may inhibit competi-
tively the binding of eNOS to caveolin, thereby activating
eNOS.
3.3. SPC-induced endothelium-dependent vasorelaxation
We further examined the e¡ects of SPC on coronary arterial
tone with or without endothelium. SPC (20 WM) caused a
relaxation of coronary arteries with endothelium precon-
tracted by 100 nM U-46619. The SPC-induced relaxation
was blocked by an inhibitor for all isoforms of NOS (3 mM
L-NMMA) [27], but not by a speci¢c inhibitor for iNOS (100
WM TRIM) [28] (Fig. 5A). The presence of endothelium was
con¢rmed by the addition of 1 WM BK at the end of each
experiment. SPC had no relaxing e¡ect on the bovine coro-
nary arteries without endothelium precontracted by U-46619
(Fig. 5B). The endothelium-dependent relaxation was not ob-
served in case of treatment with phosphocholine and sphingo-
sine, both metabolites of SPC [1] (data not shown). This evi-
dence shows that SPC directly causes endothelium-dependent
vasorelaxation, as mediated by NO, which may be produced
by the activation of eNOS through a [Ca2]i increase in en-
dothelial cells.
3.4. Physiological implications
SPC is produced by N-deacylation of sphingomyelin, one of
the most abundant membrane lipids, although the enzyme
regulating this step has yet to be identi¢ed. On the other
hand, sphingomyelin, a precursor of SPC, is also converted
to ceramide by the activation of sphingomyelinase in response
to physiological stimuli, such as Fas and tumor necrosis fac-
tor-K [29^31]. Therefore, activation of sphingomyelinase may
also inhibit the conversion from sphingomyelin to SPC by
consumption of sphingomyelin, resulting in a decrease in cel-
lular SPC. Tissue accumulation of SPC was observed in pa-
tients with Niemann-Pick disease, in which sphingomyelinase
is de¢cient [31,32], thus sphingomyelinase may regulate the
production of SPC. In addition, since oxidized LDL activates
sphingomyelinase in human macrophages [33], oxidized LDL
may inhibit SPC production by activating sphingomyelinase
and thereby suppress the endothelium-dependent vasorelaxa-
tion mediated by SPC, as demonstrated in the present study.
This notion is supported by ¢ndings that endothelium-de-
pendent relaxation is impaired in the isolated arteries exposed
to oxidized LDL [34]. The impairment of endothelium-de-
pendent vasorelaxation plays an important role in vascular
hypercontractility observed in cardiovascular diseases, such
as hypertension, vasospasm, and ischemic heart disease. Our
experiments are ongoing in an attempt to clarify the patho-
physiological role of the sphingomyelin-SPC pathway in vas-
cular disease.
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